Alpha Cognition Inc. (NASDAQ: ACOG) reported second-quarter 2026 results that underscore a strengthening launch trajectory for its Alzheimer's treatment ZUNVEYL, even as broader payer implementation remains a work in progress. The company's net product revenue grew 71% sequentially to $6.0 million, with bottles dispensed increasing 37% to 8,294, and June emerged as the strongest demand month since launch, reaching 2,997 bottles. These figures are particularly notable given that they were achieved without a material stocking benefit or new formulary wins, suggesting the growth is driven by underlying demand and improved commercial execution.
The demand acceleration is reflected in key adoption metrics: the quarter saw 1,347 prescribers, of which 1,024 were repeat prescribers, and cumulative writers reached 1,908. Additionally, 1,095 long-term care facilities generated prescriptions during the quarter, indicating broadening acceptance across care settings. Despite downstream pharmacy benefit manager (PBM) implementation remaining at approximately 16%, the company has demonstrated that prescriber and facility productivity can drive growth even with limited payer access. This suggests a dual path forward: continued expansion within the current prescriber base and incremental upside as PBM coverage widens.
Management indicated that growth continued into the third quarter, reinforcing the positive momentum. The company is also balancing commercial investment with a growing evidence base, having lowered its full-year 2026 R&D and SG&A guidance to $50 million-$54 million while maintaining its target of operating profitability by 2027. Upcoming milestones include the CONVERGE data readout expected in the third quarter of 2026, the ongoing RESOLVE study, and the sublingual program, which awaits comparative pharmacokinetic results. These potential catalysts could further enhance the company's position as it works toward greater operating leverage.
The results suggest that Alpha Cognition is executing well in a challenging access environment. The fact that demand is accelerating without broader formulary activation points to the product's acceptance among physicians and facilities, and as PBM implementation gradually expands, the company could see a significant boost. With a clear path to profitability and multiple data readouts on the horizon, the company appears well-positioned for sustained growth. Investors and industry observers will be watching closely as these developments unfold, particularly the CONVERGE data and any progress on payer negotiations, which could serve as key inflection points for the stock.
